Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post about an article on X:
“HSPC: personalized treatment intensification.
ADT alone is no longer the standard. ARPIs, docetaxel, and RT improve outcomes in selected HSPC subgroups.
PSMA PET refines staging and patient selection, while AKT inhibitors, PARP inhibitors, and radioligand therapies are emerging options. Toxicity-aware personalization is essential.”
Title: Personalized intensification of treatment for hormone-sensitive prostate cancer
Authors: Michael Cilento, Lisa Butler, Louise Emmett, Christopher Sweeney
Read the Full Article.
More posts featuring Diego A. Díaz-García on OncoDaily.